HC Wainwright reiterated their buy rating on shares of Oculis (NASDAQ:OCS – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $39.00 target price on the stock. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.27) EPS, Q1 2027 earnings at ($0.66) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.69) EPS.
A number of other research analysts also recently commented on the stock. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Guggenheim dropped their price objective on shares of Oculis to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. JPMorgan Chase & Co. cut their target price on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.57.
Read Our Latest Stock Report on Oculis
Oculis Trading Up 0.7%
Oculis (NASDAQ:OCS – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.10. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.26 million. Oculis had a negative return on equity of 39.24% and a negative net margin of 8,613.92%. As a group, analysts predict that Oculis will post -1.99 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Braidwell LP purchased a new stake in shares of Oculis during the 2nd quarter worth about $11,570,000. Goldman Sachs Group Inc. grew its stake in shares of Oculis by 103.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 141,688 shares of the company’s stock valued at $1,323,000 after buying an additional 72,186 shares in the last quarter. Checkpoint Capital L.P. bought a new stake in shares of Oculis in the 3rd quarter valued at approximately $929,000. Alps Advisors Inc. increased its holdings in Oculis by 40.7% in the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after buying an additional 23,600 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Oculis by 9.1% in the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after buying an additional 5,813 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Recommended Stories
- Five stocks we like better than Oculis
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
